Lupin unveils Mirabegron ER tablets in US
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-22 06:39 GMT | Update On 2024-06-20 18:59 GMT
Advertisement
Mumbai: Global pharma major Lupin Limited has announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).
Read also: Lupin unveils first generic version of Oracea in US
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.
The Medical Dialogues team earlier reported that Lupin Limited had launched the first generic version of Oracea (Doxycycline Capsules, 40 mg) in the United States.
Read also: USFDA approves Lupin Valbenazine Capsules
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.